Oncosec Medical Incorporated · OTC:ONCSQ
Oncosec Medical — Investor Presentation (November 2022)
27 slides from Oncosec Medical's investor presentation, November 2022
Slide 1: OncoSec Overview
OncoSec Overview Corporate Presentation November 2022
Slide 2: Risk Factors and Forward-Looking Statements
Risk Factors and Forward-Looking Statements This presentation contains forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Com
Slide 3: OncoSec as a future leader of immuno-oncology therapy
OncoSec as a future leader of immuno-oncology therapy Addressing unmet clinical needs by leveraging innovative intra-tumor drug delivery Vision • We aspire to ignite the immune system to eradicate tumors and restore patients’ lives. Mission • Provide safe and effective solutions for cancer patients
Slide 4: Harnessing the immune system to eradicate cancer
Melanoma: Advanced Melanoma: Neoadjuvant Triple Negative Breast Harnessing the immune system to eradicate cancer • Proprietary electroporation (EP) platform designed to elicit tumor-directed immune cell ImmunoPulse® activation against cutaneous and subcutaneous tumors using intratumoral delivery of
Slide 5: Investment opportunity
Investment opportunity Differentiated Best-in-Class Robust Delivery Platform Therapeutic Potential Development Strategy ImmunoPulse® platform TAVO™-EP differentiates Management team with big designed to overcome key by mechanism of action pharma and biotech experience immuno-therapy and shows effica
Slide 6: ImmunoPulse platform designed to address key clinical unmet needs
ImmunoPulse® platform designed to address key clinical unmet needs • Distinctive intratumoral delivery by EP applicable to cutaneous and Illustration of electroporation (EP) process subcutaneous solid tumors clinical procedure requires only a few seconds per individual EP event • Clinical efficacy w
Slide 7: Positioning of OncoSec's TAVO-EP
Positioning of OncoSec’s TAVO™-EP 7
Slide 8: The IO market driven by checkpoint modulators is growing rapidly
The IO market driven by checkpoint modulators is growing rapidly Global Market Analysis and Forecast of Immuno-Oncology Approaches • Immuno-oncology (IO) approaches have demonstrated significant, durable response 160 $143 B rates in a broad range of cancer types 140 120 • In 2021, IO therapies captu
Slide 9: External market research projects rapid growth of the intratumoral market
External market research projects rapid growth of the intratumoral market • Several independent market reports project the intratumoral cancer therapy market to grow rapidly − Monoclonal antibodies, vaccines, checkpoint inhibitors, cell therapies, immune system modulators, adoptive cell transfer, cy
Slide 10: TAVO-EP enables delivery of well-validated anti-tumor agent IL-12
TAVO™-EP enables delivery of well-validated anti-tumor agent IL-12 • IL-12 is an important pro-inflammatory cytokine that stimulates a broad set of immune effector cells to generate a strong anti-tumor response • Killing of cancer cells exposes antigen presenting cells to tumor antigens and results
Slide 11: Future expansion opportunities for ONCS growth into a leading IO company
Future expansion opportunities for ONCS growth into a leading IO company Improve Therapeutic • Plasmid DNA as backbone for ONCS pipeline, with a small portfolio of Reach w/ Combination key immune regulators Therapeutic modalities MDSC that are applicable Approaches Treg for Targets Targets • Expansi
Slide 12: Clinical Programs
Clinical Programs @oncosec
Slide 13: Additional Programs
Melanoma: Advanced Melanoma: Neoadjuvant Triple Negative Breast Sharpened focus on melanoma and upside potential in other tumor types Regimen Trial Indication Partner Phase 1 Phase 2 Pivotal Key Focus TAVO™ + 4 KEYNOTE-6951 Advanced Melanoma BICR data readout in 1Q23 Pembrolizumab Additional Program
Slide 14: TAVO-EP is targeting the large, growing melanoma market
Melanoma: Advanced Melanoma: Neoadjuvant TAVO™-EP is targeting the large, growing melanoma market Major Markets1 Incidence Global Market Size (2021 – 2028) +102% 250 K CAGR 1.5% $20 B $16.4 B 200 K $15 B $3.5 B $0.5 B $3.2 B $0.3 B 150 K $10 B $8.1 B $2.2 B $1.9 B $0.6 B 206 K 212 K 219 K 226 K $0.7
Slide 15: Great unmet need remains in melanoma
Melanoma: Advanced Melanoma: Neoadjuvant Great unmet need remains in melanoma Primary Resistance Secondary Resistance Most patients receive PD-1 Among initial PD-1 responders, mono- or combo-therapy in the ~40% acquire resistance and 1L, yet 40 – 65% fail to respond1 progress within 5 years2 Key Unm
Slide 16: Immunotherapy is the preferred treatment option for advanced melanoma
Melanoma: Advanced Melanoma: Neoadjuvant Immunotherapy is the preferred treatment option for advanced melanoma Opportunity Assessment and Implications for Commercialization of TAVO™ + Pembrolizumab in PD-1-Resistant Melanoma in the US; Bluestar* July 2021.I 1L/2L/3L+: first/second/third line treatme
Slide 17: TAVO-EP plus pembrolizumab is seen as attractive treatment alternative
Melanoma: Advanced Melanoma: Neoadjuvant TAVO™-EP plus pembrolizumab is seen as attractive treatment alternative Opportunity Assessment and Implications for Commercialization of TAVO™ + Pembrolizumab in PD-1-Resistant Melanoma in the US; Bluestar* July 2021. CTLA-4i: anti-CTLA-4 antibodies; EP: elec
Slide 18: KEYNOTE-695 trial design
Melanoma: Advanced Melanoma: Neoadjuvant KEYNOTE-695 trial design TAVO™ + pembrolizumab Survival Follow-up Patients with advanced melanoma and documented confirmed progression on immediate Key eligibility criteria: prior anti-PD-1 antibody therapy TAVO™-EP Days 1, 5, 8 q6w Treatment: Pembrolizumab 2
Slide 19: KEYNOTE-695 Cohort 1a: RECIST v1.1 response
Melanoma: Advanced Melanoma: Neoadjuvant KEYNOTE-695 Cohort 1a: RECIST v1.1 response Efficacy Evaluable (N=101) n (%) Objective Response Rate (CR + PR) 19 (18.8) 95% Exact Binomial Confidence Interval 11.7, 27.8 Complete Response (CR) 3 ( 3.0) Partial Response (PR) 16 (15.8) Stable Disease (SD) 22 (
Slide 20: KEYNOTE-695 Cohort 1a: best change in measurable tumor lesions
Melanoma: Advanced Melanoma: Neoadjuvant KEYNOTE-695 Cohort 1a: best change in measurable tumor lesions Efficacy evaluable subject with post-baseline target lesion assessment Efficacy Evaluable (all subjects) n (%); N = 101 Objective Response Rate (CR + PR), n(%) 19 (18.8) 95% Exact Binomial Confide
Slide 21: KEYNOTE-695 Cohort 1a: duration of response
Melanoma: Advanced Melanoma: Neoadjuvant KEYNOTE-695 Cohort 1a: duration of response RECIST v1.1 Responders, N = 19 100 Overall (N=19) Status n (%) Event 6 (31.6) 80 Responding Probability (% ) Censored 13 (68.4) 60 Duration of Response months (95% CI) Q1 (95% CI) 8.3 (5.0, NE) 40 Median (95% CI) NE
Slide 22: KEYNOTE-695 Cohort 1a: overall survival (OS)
Melanoma: Advanced Melanoma: Neoadjuvant KEYNOTE-695 Cohort 1a: overall survival (OS) Overall Survival N = 105 100 Overall (N=105) Median months (95% CI) 22.7 (14.4, 35.5) 80 Status, n (%) Overall Survival Probability (%) Death 61 (58.1) 60 Censored 44 (41.9) 40 OS rate (95% CI) at 6 months 91.4 (84
Slide 23: TAVO-EP + pembrolizumab comparison to benchmarks in post PD-1 setting
KEYNOTE-695 Cohort 1a: Melanoma: Advanced Melanoma: Neoadjuvant TAVO™-EP + pembrolizumab comparison to benchmarks in post PD-1 setting • TAVO™-EP + pembrolizumab ORR1, in patients with confirmed progression on anti-PD1 therapy, was 18.8% based on investigator-assessment − Ipilimumab BICR-assessed OR
Slide 24: TAVO-EP is a well tolerated safety profile for late-stage melanoma
Melanoma: Advanced Melanoma: Neoadjuvant TAVO™-EP is a well tolerated safety profile for late-stage melanoma Company Regimen MOA Dev. Stage Safety/AEs TAVO™ + IL-12 activator Phase 2b 5.4% Grade 3 AEs, no Grade 4/5 TEAEs Pembrolizumab Cellular Lifileucel/LN-144 Phase 2 82% Grade 3+ thrombocytopenia,
Slide 25: KEYNOTE-695 Cohort 1a: conclusions
Melanoma: Advanced Melanoma: Neoadjuvant KEYNOTE-695 Cohort 1a: conclusions • The observed ORR1 of 18.8% with TAVO™-EP + pembrolizumab, in patients refractory to anti-PD-1 therapy, demonstrates that intratumoral IL-12 provides a critical immune regulatory signal that has the potential to reverse tum
Slide 26: Experienced industry leaders with track record of success
Experienced industry leaders with track record of success Leadership Team Board of Directors Linda Shi, M.D. Ph.D. Robert H. Arch, Ph.D Chair George Chi President and Chief Financial Officer Robert H. Arch, Ph.D. Chief Executive Officer Director Stephany Foster, M.B.A. Sandra Aung, Ph.D Robert J. De
Slide 27: Thank you!
®)oncosec IMMUNOTHERAPIES Thank you!
OncoSec Medical — Investor Presentation (November 2022) on 6ix